At the EHDN plenary meeting in the Hague in September 2016 and in a subsequent press release, Teva Pharmaceutical Industries reported the preliminary results of the PRIDE-HD trial, an exploratory phase 2 trial of pridopidine endorsed by the EHDN

Professor Francesco Muntoni, University College London, is talking about videos of children given an experimental drug for treating spinal muscular atrophy. This genetic disorder involves the deterioration of nerves connecting the brain and spinal cord to the body’s muscles.